Sable · Reference
Retatrutide: UK Research Peptide Reference
Verified reference data for research use only.
Research use only. Not for consumption. No health claims.
Last updated 2026-10-10
Product page · Questions · JSON
Research questions
research_context
Retatrutide mechanism of action?
In the research literature, Retatrutide is described as a single-molecule agonist at GIP, GLP-1 and glucagon receptors (a 'triple agonist') reported in incretin receptor pharmacology research. It is classed as a peptide (lipidated). This describes its use as a laboratory research tool only, not any effect in people. Sable Peptides supplies it for laboratory research use only; it is not for human consumption.
Source: https://cdn.caymanchem.com/cdn/insert/45527.pdfhttps://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13769&tab=structure
Cite this
Plain
Sable Peptides. (2026). Retatrutide: UK Research Peptide Reference. UK Research Peptide Reference. Retrieved 2026-10-11, from https://www.sablepeptides.co.uk/ref/retatrutide
APA
Sable Peptides. (2026, October 10). Retatrutide: UK Research Peptide Reference. UK Research Peptide Reference. https://www.sablepeptides.co.uk/ref/retatrutide
BibTeX
@misc{sable_retatrutide_2026, author = {{Sable Peptides}}, title = {{Retatrutide: UK Research Peptide Reference}}, year = {2026}, howpublished = {\url{https://www.sablepeptides.co.uk/ref/retatrutide}}, note = {Accessed 2026-10-11. CC BY 4.0}}Badge
<a href="https://www.sablepeptides.co.uk/ref"><img src="https://www.sablepeptides.co.uk/badge/ref.svg" alt="Data: UK Research Peptide Reference — Sable Peptides" width="220" height="40"></a>